

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

<p style="text-align: center;">U.S. PATENT & TRADEMARK OFFICE APR 15 2015 C50 Substitute Patent 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	09/393,590
				Filing Date	09/09/1999
				First Named Inventor	Elizabeth Moyer
				Art Unit	1645
				Examiner Name	Devi, S.J.N.
Sheet	1	of	3	Attorney Docket Number	31242-701.201

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
SD		6,113,915	09-05-2000	Kei Roger Aoki et al	424/236.1
SD		6,139,845	10-31-2000	Stephen Donovan	424/236.1
SD		6,350,455 B1	02-26-2002	Stephen Donovan	424/239.1
SD		6,358,513 B1	03-19-2002	Martin A. Voet et al	424/239.1

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
SD		HENRY S. SACKS ET AL, <i>Clostridium botulinum</i> Type E Toxin: Effect of pH and Method of Purification on Molecular Weight, <i>Applied Microbiology</i> , September 1974, p. 374-382, Vol. 28:3, American Society for Microbiology, USA			
SD		IWAO OHISHI ET AL, Purification of <i>Clostridium botulinum</i> Type F Progenitor Toxin, <i>Applied Microbiology</i> , December 1974, p. 923-928, Vol. 28:6, American Society for Microbiology, USA			
SD		IWAO OHISHI ET AL, Molecular Construction of <i>Clostridium botulinum</i> Type F Progenitor Toxin, <i>Applied Microbiology</i> , April 1975, p. 444-447, Vol. 29:4, American Society for Microbiology, USA			
SD		SHUNJI SUGII ET, Correlation Between Oral Toxicity and In Vitro Stability of <i>Clostridium botulinum</i> Type A and B Toxins of Different Molecular Sizes, <i>Infection and Immunity</i> , June 1977, p. 910-914, Vol. 16:3, American Society for Microbiology, USA			
Examiner Signature		SD	Date Considered	July 05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.


Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

<p style="text-align: center;">Substitute for INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)</p>				Complete if Known			
				Application Number		09/393,590	
				Filing Date		09/09/1999	
				First Named Inventor		Elizabeth Moyer	
				Art Unit		1645	
				Examiner Name		Devi, S.J.N.	
Sheet	2	of	3	Attorney Docket Number	31242-701.201		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
SD		IWAO OHISHI ET AL, Activation of Botulinum Toxins in the Absence of Nicking, Infection and Immunity, August 1977, p. 402-407, Vol. 17:2, American Society for Microbiology, USA			
		ALBERT L. LEHINIGER, The Molecular Basis of Cell Structure and Function, Biochemistry (Second Edition), July 1978, 45-50, Worth Publishers, Inc., New York, USA			
		IWAO OHISHI ET AL, Oral Toxicities of <i>Clostridium botulinum</i> Type C and D Toxins of Different Molecular Sizes, Infection and Immunity, May 1980, p. 303-309; Vol. 28:2			
		IWAO OHISHI ET AL, Purification and Characterization of Two Components of Botulinum C ₂ Toxin, Infection and Immunity, December 1980, p. 668-673, Vol. 30:3			
		LEON LACHMAN, Ph.D. ET AL, The Theory and Practice of Industrial Pharmacy, third edition, 1986, p. 458-460, Lea & Febiger, Philadelphia, USA			
		FLORA CHEN ET AL, Biophysical Characterization of the Stability of the 150-Kilodalton Botulinum Toxin, the Nontoxic Component, and the 900-Kilodalton Botulinum Toxin Complex Species, Infection and Immunity, June 1988, p. 2420-2425, Vol. 66:6, American Society for Microbiology, USA			
SD		J. MELLING ET AL, Clostridium Botulinum Toxins: Nature and Preparation for Clinical Use; Eye, 1988:2, p. 16-23			
Examiner Signature		SD	Date Considered	July 05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



<p>Substitute for form 1449/1449A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)</p>				Complete if Known	
				Application Number	09/393,590
				Filing Date	09/09/1999
				First Named Inventor	Elizabeth Moyer
				Art Unit	1645
				Examiner Name	Devi, S.J.N.
Sheet	3	of	3	Attorney Docket Number	31242-701.201

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
SD		J. HALOUZKA ET AL, Effect of pH on the Stability of Type-C Toxin of <i>Clostridium botulinum</i> , <i>Folia Microbiol</i> , 1992, p. 157-158, Vol. 37:2,			
		GIAMPIETRO SCHIAVO ET AL, Botulinum G Neurotoxin Cleaves VAMP/Synaptobrevin at a Single Ala-Ala Peptide Bond, <i>The Journal of Biological Chemistry</i> , August 12, 1994, p. 20213-20216, Vol. 269:32, The American Society for Biochemistry and Molecular Biology, Inc., USA			
		ROSSELLA PELLIZZARI ET AL, Structural Determinants of the Specificity for Synaptic Vesicle-associated Membrane Protein/Synaptobrevin of Tetanus and Botulinum Type B and G Neurotoxins, <i>The Journal of Biological Chemistry</i> , August 1996, p. 20353-20358, Vol. 271:34, The American Society for Biochemistry and Molecular Biology, Inc., USA			
SD		KAY MCLELLAN ET AL, Therapeutic Botulinum Type A Toxin: Factors Affecting Potency, <i>Toxicon</i> , 1996, p. 975-985, Vol. 34:9, Elsevier Science Ltd, Great Britain			
Examiner Signature		SD	Date Considered	July 05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.